Статья
Настоящая работа представляет собой аналитический обзор литературы, посвященный роли воспалительных биомаркеров в механизмах формирования артериальной гипертензии (АГ). Подготовка обзора проводилась в соответствии с общими принципами написания аналитических обзоров. Поиск релевантных публикаций осуществлялся в электронных базах данных: PubMed/MEDLINE, Scopus, Web of Science, Google Scholar, eLIBRARY.RU. Критерии включения для поиска источников соответствовали принципам PICOS (Population, Intervention/Exposure, Comparison, Outcome, Study Design). Характеристика участников (Population): взрослые пациенты (≥ 18 лет) с эссенциальной АГ. В качестве биомаркеров (Exposure) выбирали лабораторные иммуновоспалительные маркеры (высокочувствительный С-реактивный белок, фактор некроза опухоли альфа, матриксные металлопротеиназы 2 и 9, липокалин, эндотелин-1, интерлейкин 6). Сравнение (Comparison) биомаркеров проводили с группой без АГ или с уровнем этих биомаркеров после вмешательства (для больных АГ). Исходами (Outcomes) служили наличие АГ, уровни артериального давления, а также связи биомаркеров с поражением органов-мишеней. Типы исследований (Study Design) включали когортные, поперечные, случай–контроль, интервенционные исследования нейромодулирующих вмешательств (ренальная денервация). Поиск проводился среди русскоязычной и англоязычной литературы. Глубина поиска охватывала период в 30 лет (с 1996 по 2025 гг.). Для формирования поискового запроса использовались комбинации ключевых слов и терминов MeSH, включая: “arterial hypertension”, “inflammation markers”, “C-reactive protein”, “matrix metalloproteinases”, “lipocalin”, “endothelin-1”, “interleukin-6”, “TNF-alpha”, “systemic inflammation indices”, “renal denervation”. Поисковые запросы адаптировались под требования каждой конкретной базы данных. Значительное внимание уделено связи воспалительных цитокинов с развитием патологических изменений органов-мишеней. Также продемонстрирована связь воспалительных биомаркеров с развитием стенозирующего атеросклероза у пациентов с тяжелыми формами артериальной гипертензии и показано иммуномодулирующее действие ренальной денервации.
1. Virani S, Alonso A, Benjamin E, Bittencourt M, Callaway C, Carson A, et al. Heart disease and stroke statistics — 2020 update: a report from the American Heart Association. Circulation. 2020; 141(9):e139–e596. https://doi.org/10.1161/CIR.0000000000000757
2. Unger T, Borghi C, Charchar F, Khan N, Poulter N, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension practice guidelines. Hypertension. 2020;75(6):1334– 1357. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026
3. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1923–1994. https://doi.org/10.1016/S0140-6736(18)32225-6
4. Blacher J, Evans A, Arveiler D, Amouyel P, Ferrières J, Bingham A, et al. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: The PRIME Study. J Hum Hypertens. 2010;24(1):19–26. https://doi.org/10.1038/jhh.2009.34
5. Lieb W, Enserro D, Sullivan L, Vasanet R. Residual cardiovascular risk in individuals on blood pressure-lowering treatment. J Am Heart Assoc. 2015;4(11):e002155. https://doi.org/10.1161/JAHA.115.002155
6. Norlander A, Madhur M, Harrison D. The immunology of hypertension. J Exp Med. 2018;215(1):21–33. https://doi.org/10.1084/jem.20171773
7. Madhur M, Elijovich F, Alexander M, Pitzer A, Ishimwe J, Van Beusecum J, et al. Hypertension: do inflammation and immunity hold the key to solving this epidemic? Circ Res. 2021;128(7):908– 933. https://doi.org/10.1161/CIRCRESAHA.121.318052
8. Satou R, Penrose H, Navar G. Inflammation as a regulator of the renin-angiotensin system and blood pressure. Curr Hypertens Rep. 2018;20(12):100. https://doi.org/10.1007/s11906-018-0900-0
9. Jayedi A, Rahimi K, Bautista L, Nazarzadeh M, Zargar M, Shab-Bidar S. Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies. Heart. 2019;105(9):686– 692. https://doi.org/10.1136/heartjnl-2018-314216
10. Caillon A, Schiffrin E. Role of inflammation and immunity in hypertension: recent epidemiological, laboratory, and clinical evidence. Curr Hypertens Rep. 2016;18(3):21. https://doi.org/10.1007/s11906-016-0628-7
11. Guzik T, Touyz R. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 2017;70(4): 660–667. https://doi.org/10.1161/HYPERTENSIONAHA.117.07802
12. Айвазян Б.Г., Парцерняк С.А., Лебедева И.А., Касаткин А.Е., Голубова В.В., Парцерняк Е.С. Иммуновоспалительные маркеры и параметры сосудистой жесткости у мужчин с артериальной гипертензией и коморбидностью. Кардиология: новости, мнения, обучение. 2026;14(1):24–30. https://doi.org/10.33029/2309-1908-2026-14-1-24-30
13. Bautista L, Vera L, Arenas I, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19(2):149–154. https://doi.org/10.1038/sj.jhh.1001785
14. Yu X, Yang Z, Yu M. Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage. Ren Fail. 2010;32(4):475–479. https://doi.org/10.3109/08860221003664280
15. Hage F. C-reactive protein and hypertension. J Hum Hypertens. 2014;28(7):410–415. https://doi.org/10.1038/jhh.2013.111
16. Barbaro N, Fontana V, Modolo R, De Faria A, Sabbatini A, Fonseca F, et al. Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers. Blood Press. 2015;24(1):7–13. https://doi.org/10.3109/08037051.2014.940710
17. Kansui Y, Matsumura К, Morinaga Y, Inoue M, Kiyohara K, Ohta Y, et al. C-reactive protein and incident hypertension in a worksite population of Japanese men. J Clin Hypertens (Greenwich). 2019;21(4):524–532. https://doi.org/10.1111/jch.13510
18. Агзамова Ш.А., Ахмедова Ф.М., Хасанова Г.М. Прогностическая роль высокочувствительного С реактивного белка при формировании эссенциальной артериальной гипертензии у детей. Science and Education. 2023;4(4): 362–366
19. Sesso H, Wang L, Buring J, Ridker P, Gaziano J. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension. 2007;49(2):304–310. https://doi.org/10.1161/01.HYP.0000252664.24294.ff
20. King D, Egan B, Mainous A, Geesey M. Elevation of C-reactive protein in people with prehypertension. J Clin Hypertens (Greenwich). 2004;6(10):562–568. https://doi.org/10.1111/j.1524-6175.2004.03577.x
21. Mattace-Raso F, Verwoert G, Hofman A, Witteman J. Inflammation and incident-isolated systolic hypertension in older adults: the Rotterdam study. J Hypertens. 2010;28(5):892–895. https://doi.org/10.1097/HJH.0b013e328336ed26
22. Bautista L, López-Jaramillo P, Vera L, Casas J, Otero A, Guaracao A. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens. 2001;19(5):857–861. https://doi.org/10.1097/00004872-200105000-00004
23. Sung K, Suh J, Kim B, Kang J, Kim H, Lee M, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens. 2003;16(6):429–433. https://doi.org/10.1016/s0895-7061(03)00566-1
24. Ветошкин А.С., Шуркевич Н.П., Симонян А.А., Гапон Л.И., Карева М.А., Семерикова А.М. Артериальная гипертония в Арктике: роль стресса и вегетативной дисфункции, гендерные различия. Сибирский журнал клинической и экспериментальной медицины. 2024;39(1):83–93. https://doi.org/10.29001/2073-8552-2024-39-1-83-93
25. Song W, Zhang C, Tang J, Li Y, Jiao T, Lin X, et al. Hypersensitive C-reactive protein as a potential indicator for predicting left ventricular hypertrophy in elderly community-dwelling patients with hypertension. BMC Cardiovasc Disord. 2023;23(1):480. https://doi.org/10.1186/s12872-023-03509-z
26. Cortez A, Muxfeldt E, Cardoso C, Salles G. Prognostic value of C-reactive protein in resistant hypertension. Am J Hypertens. 2016;29(8):992–1000. https://doi.org/10.1093/ajh/hpw011
27. Seyfeli E, Sarli B, Saglam H, Karatas C, Ozkan E, Ugurlu M. The relationship between high-sensitivity C-reactive protein levels and left ventricular hypertrophy in patients with newly diagnosed hypertension. J Clin Hypertens (Greenwich). 2016;18(7):679– 684. https://doi.org/10.1111/jch.12734
28. Parks W, Wilson C, Lopez-Boado Y. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol. 2004;4(8):617–629. https://doi.org/10.1038/nri1418
29. Manicone A, McGuire J. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol. 2008;19(1):34– 41. https://doi.org/10.1016/j.semcdb.2007.07.003
30. Taherkhani S, Sheibani M, Mohammadkhanizadeh A, Virag J, Braz L, Azizi Y. Metalloproteinases (MMPs) in hypertensive disorders: role, function, pharmacology, and potential strategies to mitigate pathophysiological changes. Front Pharmacol. 2025;16:1559288. https://doi.org/10.3389/fphar.2025.1559288
31. Sainio A, Järveläinen H. Extracellular matrix-cell interactions: Focus on therapeutic applications. Cell Signal. 2020;66:109487. https://doi.org/10.1016/j.cellsig.2019.109487
32. Urbanczyk M., Layland S, Schenke-Layland K. The role of extracellular matrix in biomechanics and its impact on bioengineering of cells and 3D tissues. Matrix Biol. 2020;85-86:1–14. https://doi.org/10.1016/j.matbio.2019.11.005
33. Kostov K, Blazhev A. Changes in serum levels of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in patients with essential hypertension. Bioengineering (Basel). 2022;9(3):119. https://doi.org/10.3390/bioengineering9030119
34. Harvey A, Montezano A, Lopes R, Rios F, Touyz R. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol. 2016;32(5):659–668. https://doi.org/10.1016/j.cjca.2016.02.070
35. Marchesi C, Dentali F, Nicolini E, Maresca A, Tayebjee M, Franz M, et al. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens. 2012;30(1):3–16. https://doi.org/10.1097/HJH.0b013e32834d249a
36. Rajzer M, Wojciechowska W, Kameczura T, Olszanecka A, Fedak D, Terlecki M, et al. The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases. Arch Med Sci. 2017;13(4):760–770. https://doi.org/10.5114/aoms.2016.58825
37. Bisogni V, Cerasari A, Pucci G, Vaudo G. Matrix metalloproteinases and hypertension-mediated organ damage: current insights. Integr Blood Press Control. 2020;13:157–169. https://doi.org/10.2147/IBPC.S223341
38. Saglam M, Karakaya O, Esen A, Barutcu I, Dogan S, Karavelioglu Y, et al. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects. Tohoku J Exp Med. 2006;208(2):117–122. https://doi.org/10.1620/tjem.208.117
39. Zile M, DeSantis S, Baicu C, Stroud R, Thompson S, McClure C, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Hear Fail. 2011;4(3):246– 256. https://doi.org/10.1161/CIRCHEARTFAILURE.110.958199
40. Toba H, Lindsey M. Extracellular matrix roles in cardiorenal fibrosis: potential therapeutic targets for CVD and CKD in the elderly. Pharmacol Ther. 2019;193:99–120. https://doi.org/10.1016/j.pharmthera.2018.08.014
41. Pulido-Olmo H, García-Prieto C, Álvarez-Llamas G, Barderas M, Vivanco F, Aranguez I, et al. Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria. Clin Sci (Lond). 2016;130(7):525–538. https://doi.org/10.1042/CS20150517
42. Friese R, Rao F, Khandrika S, Thomas B, Ziegler M, Schmid-Schönbein G, et al. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens. 2009;31(7):521–533. https://doi.org/10.3109/10641960802668730
43. Xu T, Zhang Y, Li Y, Zhu D, Gao P. The association of serum inflammatory biomarkers with chronic kidney disease in hypertensive patients. Ren Fail. 2014;36(5):666–672. https://doi.org/10.3109/0886022X.2014.890002
44. Rodríguez-Sánchez E, Navarro-García J, Aceves-Ripoll J, Álvarez-Llamas G, Segura J, Barderas M, et al. Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. Nefrología (Engl Ed). 2019;39(2):184–191. https://doi.org/10.1016/j.nefro.2018.08.009
45. Cheng Z, Limbu M, Wang Z, Liu J, Liu L, Zhang X, et al. MMP-2 and 9 in chronic kidney disease. Int J Mol Sci. 2017; 18(4):776. https://doi.org/10.3390/ijms18040776
46. Belo V, Guimarães D, Castro M. Matrix metalloproteinase 2 as a potential mediator of vascular smooth muscle cell migration and chronic vascular remodeling in hypertension. J Vasc Res. 2015;52(4):221–231. https://doi.org/10.1159/000441621
47. Parente J, Pereira C, Oliveira-Paula G, Tanus-Santos J, Tostes R, Castro M. Matrix metalloproteinase-2 activity is associated with divergent regulation of calponin-1 in conductance and resistance arteries in hypertension-induced early vascular dysfunction and remodelling. Basic Clin Pharmacol Toxicol. 2017;121(4):246– 256. https://doi.org/10.1111/bcpt.12787
48. Wang M, Zhang J, Telljohann R, Jiang L, Wu J, Monticone R, et al. Chronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressure. Hypertension. 2012;60(2):459–466. https://doi.org/10.1161/HYPERTENSIONAHA.112.191270
49. Morillas P, Quiles J, Andrade H, Castillo J, Tarazón E, Roselló E, et al. Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage. J Hypertens. 2013;31(8):1611–1617. https://doi.org/10.1097/HJH.0b013e3283614c1c
50. Valente F, Andrade D, Cosenso-Martin L, Cesarino C, Guimarães S, Guimarães V, et al. Plasma levels of matrix metalloproteinase-9 are elevated in individuals with hypertensive crisis. BMC Cardiovasc Disord. 2020;20(1):132. https://doi.org/10.1186/s12872-020-01412-5
51. Личикаки В.А., Мордовин В.Ф., Фальковская А.Ю., Зюбанова И.В., Манукян М.А., Солонская Е.И. и др. Особенности коронарной патологии и ее связь с маркерами фиброза миокарда у больных с резистентной гипертензией. Российский кардиологический журнал. 2023;28(6):5394.https://doi.org/10.15829/1560-4071-2023-5394
52. Simоes G, Pereira T, Caseiro A. Matrix metalloproteinases in vascular pathology. Microvasc Res. 2022;143:104398. https://doi.org/10.1016/j.mvr.2022.104398
53. Kuliczkowski W, Banaszkiewicz M, Mysiak A, Makaś G, Bil-Lula I. Does arterial hypertension affect plasma levels of matrix metalloproteinases and their tissue inhibitors in patients with stable coronary artery disease? A preliminary study. Cardiol Res Pract. 2019;2019:6921315. https://doi.org/10.1155/2019/6921315
54. Hopps E, Lo Presti R, Caimi G. Matrix metalloproteases in arterial hypertension and their trend after antihypertensive treatment. Kidney Blood Press Res. 2017;42(2):347–357. https://doi.org/10.1159/000477785
55. Wang X, Khalil R. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol. 2018;81:241–330. https://doi.org/10.1016/bs.apha.2017.08.002
56. Brown B, Williams H, George S. Evidence for the involvement of matrix-degrading metalloproteinases (MMPs) in atherosclerosis. Prog Mol Biol Transl Sci. 2017;147:197–237. https://doi.org/10.1016/bs.pmbts.2017.01.004
57. Johnson J. Metalloproteinases in atherosclerosis. Eur J Pharmacol. 2017;816:93–106. https://doi.org/10.1016/j.ejphar.2017.09.007
58. Li T, Li X, Feng Y, Dong G, Wang Y, Yang J, et al. The role of matrix metalloproteinase-9 in atherosclerotic plaque instability. Mediators Inflamm. 2020;2020:3872367. https://doi.org/10.1155/2020/3872367
59. Kremastiotis G, Handa I, Jackson C, George S, Johnson J. Disparate effects of MMP and TIMP modulation on coronary atherosclerosis and associated myocardial fibrosis. Sci Rep. 2021;11(1):23081. https://doi.org/10.1038/s41598-021-02508-4
60. Olejarz W, Lacheta D, Kubiak-Tomaszewska G. Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability. Int J Mol Sci. 2020;21(11):3946. https://doi.org/10.3390/ijms21113946
61. Tayebjee M, Nadar S, Blann A, Beevers D, MacFadyen R, Lip G. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens. 2004;17(9):764–769. https://doi.org/10.1016/j.amjhyper.2004.05.019
62. Onal I, Altun B, Onal E, Kirkpantur A, Oz S, Turgan C. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med. 2009;20(4):369–372. https://doi.org/10.1016/j.ejim.2008.10.003
63. Pesce B, Ribeiro C, Larrondo M, Ramos V, Soto L, Catalán D, et al. TNF-α affects signature cytokines of Th1 and Th17 T Cell subsets through differential actions on TNFR1 and TNFR2. Int J Mol Sci. 2022;23(16):9306. https://doi.org/10.3390/ijms23169306
64. Puszkarska A, Niklas A, Głuszek J, Lipski D, Niklas K. The concentration of tumor necrosis factor in the blood serum and in the urine and selected early organ damages in patients with primary systemic arterial hypertension. Medicine (Baltimore). 2019;98(22):e15773. https://doi.org/10.1097/MD.0000000000015773
65. Plante T, Juraschek S, Howard G, Howard V, Tracy R, Olson N, et al. Cytokines, C-reactive protein, and risk of incident hypertension in the REGARDS study. Hypertension. 2024;81(6):1244–1253. https://doi.org/10.1161/HYPERTENSIONAHA.123.22714
66. Navarro-González J, Mora C, Muros M, Jarque A, Herrera H, García J. Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. J Hypertens. 2008;26(11):2168–2175. https://doi.org/10.1097/HJH.0b013e32830e2545
67. Lindberg S, Jensen J, Mogelvang R, Pedersen S, Galatius S, Flyvbjerg A, et al. Plasma neutrophil gelatinase-associated lipocalin in the general population: association with inflammation and prognosis. Arterioscler Thromb Vasc Biol. 2014;34(9):2135–2142. https://doi.org/10.1161/ATVBAHA.114.303950
68. Park C, Choi K. Lipocalin-2, A-FABP and inflammatory markers in relation to flow-mediated vasodilatation in patients with essential hypertension. Clin Exp Hypertens. 2014;36(7):478–483
69. Araos P, Amador C. Neutrophil gelatinase-associated lipocalin as an immunomodulator in endocrine hypertension. Front Endocrinol (Lausanne). 2022;13:1006790. https://doi.org/10.3389/fendo.2022.100679
70. Buonafine M, Martinez-Martinez E, Jaisser F. More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases. Clin Sci (Lond). 2018;132(9):909–923. https://doi.org/10.1042/CS20171592
71. Malyszko J, Bachorzewska-Gajewska H, Malyszko J, Pawlak K, Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in hypertensive and normotensive patients with coronary artery disease. Nephrology (Carlton). 2008;13(2):153–156. https://doi.org/10.1111/j.1440-1797.2007.00899.x
72. Ong K-L, Tso A, Cherny S, Sham P-C, Lam T-H, Lam K, et al. Role of genetic variants in the gene encoding lipocalin-2 in the development of elevated blood pressure. Clin Exp Hypertens. 2011;33(7):484֪–491. https://doi.org/10.3109/10641963.2010.549276
73. Song E, Fan P, Huang B, Deng H-B, Cheung B, Feletou M, et al. Deamidated lipocalin-2 induces endothelial dysfunction and hypertension in dietary obese mice. J Am Heart Assoc. 2014;3(2):e000837–e000837. https://doi.org/10.1161/JAHA.114.000837
74. Полонская Я.В., Каштанова Е.В., Стахнёва Е. М., Ледовских С.Р., Шрамко В.С., Садовский Е.В. и др. Абдоминальное ожирение и уровни маркеров воспаления и адипокинов у молодых людей с артериальной гипертензией. Атеросклероз. 2024;20(2):100–107. https://doi.org/10.52727/2078-256X-2024-20-2-100-107
75. Aksan G, İnci S, Nar G, Siğirci S, Gedikli Ö, Soylu K, et al. Serum neutrophil gelatinase-associated lipocalin levels in patients with non-dipper hypertension. Clin Invest Med. 2015;38(2):E53–62. https://doi.org/10.25011/cim.v38i1.22576
76. Li D, Li H, Bauer C, Hu Y, Lewis J, Xu A, et al. Lipocalin-2 variants and their relationship with cardio-renal risk factors. Front Endocrinol (Lausanne). 2021;12:781763. https://doi.org/10.3389/fendo.2021.781763
77. Zhang C, Zhang D-D, Feng Y-M, Huang Z-Q, Xie Y-B, Zhou J, et al. Relationship between morning peak phenomenon and early renal injury NGAL in H-type hypertension. Blood Press. 2022;31(1):200–206. https://doi.org/10.1080/08037051.2022.2106186
78. Nurkoç S, Ünlü S, Şen B, Tefon A, Hasanreisoglu M, Şahinarslan A. Neutrophil gelatinase-associated lipocalin level can predict early organ damage in primary hypertensive patients: a pilot study. Anatol J Cardiol. 2023;27(9):513–518. https://doi.org/10.14744/AnatolJCardiol.2023.2991
79. Ni J, Ma X, Zhou M, Pan X, Tang J, Hao Y, et al. Serum lipocalin-2 levels positively correlate with coronary artery disease and metabolic syndrome. Cardiovasc Diabetol. 2013;12:176. https://doi.org/10.1186/1475-2840-12-176
80. Sivalingam Z, Larsen S, Grove E, Hvas A-M, Kristensen S, Magnusson N. Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease. Clin Chem Lab Med. 2017;56(1):5–18. https://doi.org/10.1515/cclm-2017-0120
81. Shibata K, Sato K, Shirai R, Seki T, Okano T, Yamashita T, et al. Lipocalin-2 exerts pro-atherosclerotic effects as evidenced by in vitro and in vivo experiments. Heart Vessels. 2020;35(7):1012– 1024. https://doi.org/10.1007/s00380-020-01556-6
82. Ergul S, Parish D, Puett D, Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28(4):652–655. https://doi.org/10.1161/01.hyp.28.4.652
83. Schiffrin E. Endothelin and endothelin antagonists in hypertension. J Hypertens. 1998;16(12Pt2):1891–1895. https://doi.org/10.1097/00004872-199816121-00007
84. Schiffrin E. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 2001;14(S3):83S–89S. https://doi.org/10.1016/S0895-7061(01)02074-X
85. Trensz F, Bortolamiol C, Kramberg M, Wanner D, Hadana H, Rey M, et al. Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension. J Pharmacol Exp Ther. 2019;368(3):462– 473. https://doi.org/10.1124/jpet.118.253864
86. Schiffrin E, Lariviere R, Li J, Sventek P. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res. 1996;33(3):235–248. https://doi.org/10.1159/000159151
87. Schiffrin EL, Pollock DM. Endothelin system in hypertension and chronic kidney disease. Hypertension. 2024;81(4): 691– 701. https://doi.org/10.1161/HYPERTENSIONAHA.123.21716
88. Kedzierski R, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol. 2001;41:851–876. https://doi.org/10.1146/annurev.pharmtox.41.1.851
89. Rautureau Y, Schiffrin E. Endothelin in hypertension: an update. Curr Opin Nephrol Hypertens. 2012;21(2):128–136. https://doi.org/10.1097/MNH.0b013e32834f0092
90. Iglarz M, Clozel M. At the heart of tissue: endothelin system and end-organ damage. Clin Sci (Lond). 2010;119(11):453–463. https://doi.org/10.1042/CS20100222
91. Chapman G, Dhaun N. Endothelin antagonism: a new era for resistant hypertension? Hypertension. 2025;82(4):611–614. https://doi.org/10.1161/HYPERTENSIONAHA.125.24606
92. Molero L, Farré J, García-Mendez A, Mateos-Caceres P, Martín C, Millás I, et al. Endothelin-1 induced proinflammatory markers in the myocardium and leukocytes of guinea-pigs: role of glycoprotein IIB/IIIA receptors. Cardiovasc Res. 2003;57(1):109– 118. https://doi.org/10.1016/s0008-6363(02)00657-0
93. Mencarelli M, Pecorelli A, Carbotti P, Valacchi G, Grasso G, Muscettola M. Endothelin receptor A expression in human inflammatory cells. Regul Pept. 2009;158(1–3):1–5. https://doi.org/10.1016/j.regpep.2009.06.004
94. Tinazzi E, Puccetti A, Patuzzo G, Barbieri A, Argentino G, Confente F, et al. Endothelin receptors expressed by immune cells are involved in modulation of inflammation and in fibrosis: relevance to the pathogenesis of systemic sclerosis. J Immunol Res. 2015;2015:147616. https://doi.org/10.1155/2015/147616
95. Shinagawa S, Okazaki T, Ikeda M, Yudoh K, Kisanuki Y, Yanagisawa M, et al. T cells upon activation promote endothelin 1 production in monocytes via IFN-γ and TNF-α. Sci Rep. 2017;7(1):14500. https://doi.org/10.1038/s41598-017-14202-5
96. Zhang X, Chen Z, Zuo S, Sun H, Li X, Lu X, et al. Endothelin-a receptor antagonist alleviates allergic airway inflammation via the inhibition of ILC2 Function. Front Immunol. 2022;13:835953. https://doi.org/10.3389/fimmu.2022.835953
97. Banecki K, Dora K. Endothelin-1 in health and disease. Int J Mol Sci. 2023;24(14):11295. https://doi.org/10.3390/ijms241411295
98. Saleh M, Boesen E, Pollock J, Savin V, Pollock D. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension. 2010;56(5):942–949. https://doi.org/10.1161/HYPERTENSIONAHA.110.156570
99. Kostov K, Blazhev A. Circulating levels of endothelin-1 and big endothelin-1 in patients with essential hypertension. Pathophysiology. 2021;28(4):489–495. https://doi.org/10.3390/pathophysiology28040031
100. Ramzy D, Rao V, Tumiati L, Xu N, Sheshgiri R, Jackman J, et al. Endothelin-1 accentuates the proatherosclerotic effects associated with C-reactive protein. J Thorac Cardiovasc Surg. 2007;133(5):1137–1146. https://doi.org/10.1016/j.jtcvs.2006.11.034
101. Clozel, M. Aprocitentan and the endothelin system in resistant hypertension. Can J Physiol Pharmacol. 2022;100(7):573–583. https://doi.org/10.1139/cjpp-2022-0010
102. Solini A, Zoppini G, Orsi E, Fondelli C, Trevisan R, Vedovato M, et al. Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications. J Hypertens. 2014;32(12):2401–2410. https://doi.org/10.1097/HJH.0000000000000350
103. Rossignol P, Massy Z, Azizi M, Bakris G, Ritz E, Covic A, et al. The double challenge of resistant hypertension and chronic kidney disease. Lancet. 2015;386(10003):1588–1598. https://doi.org/10.1016/S0140-6736(15)00418-3
104. Schlaich M, Bellet M, Weber M, Danaietash P, Bakris G, Flack J, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927–1937. https://doi.org/10.1016/S0140-6736(22)02034-7
105. Danaietash P, Verweij P, Wang J-G, Dresser G, Kantola I, Lawrence M, et al. Identifying and treating resistant hypertension in PRECISION: a randomized long-term clinical trial with aprocitentan. J Clin Hypertens (Greenwich). 2022;24(7):804–813. https://doi.org/10.1111/jch.14517
106. Boutari C, Siskos F. Novel dual endothelin inhibitors in the management of resistant hypertension. Life (Basel). 2023;13(3):806. https://doi.org/10.3390/life13030806
107. Simundic T, Jelakovic B, Dzumhur A, Turk T, Sahinovic I, Dobrosevic B, et al. Interleukin 17A and toll-like receptor 4 in patients with arterial hypertension. Kidney Blood Press Res. 2017;42(1):99–108. https://doi.org/10.1159/000471900
108. Shao Y, Saredy J, Yang W, Sun Y, Lu Y, Saaoud F, et al. Vascular endothelial cells and innate immunity. J Hypertens. 2020;40(6):e138–e152. https://doi.org/10.1161/ATVBAHA.120.314330
109. Yao W, Sun Y, Wang X, Niu K. Elevated serum level of interleukin 17 in a population with prehypertension. J Clin Hypertens (Greenwich). 2015;17(10):770–774. https://doi.org/10.1111/jch.12612
110. Chen F, Chen C, Lin C. Hypertensive crisis and refractory hypertension caused by atypical hemolytic uremic syndrome and effect of eculizumab. Acta Cardiol Sin. 2018;34(5):446–449. https://doi.org/10.6515/ACS.201809_34(5).20180326D
111. Rothman A, MacFadyen J, Thuren T, Webb A, Harrison D, Guzik T, et al. Effects of interleukin-1beta inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS. Hypertension. 2020;75(2):477–482. https://doi.org/10.1161/HYPERTENSIONAHA.119.13642
112. Small H, Migliarino S, Czesnikiewicz-Guzik M, Guzik T, et al. Hypertension: focus on autoimmunity and oxidative stress. Free Radic Biol Med. 2018;125:104–115. https://doi.org/10.1016/j.freeradbiomed.2018.05.085
113. Loperena R, Van Beusecum J, Itani H, Engel N, Laroumanie F, Xiao L, et al. Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: roles of STAT3, interleukin 6 and hydrogen peroxide. Cardiovasc Res. 2018;114(11):1547–1563. https://doi.org/10.1093/cvr/cvy112
114. Шуркевич Н.П., Ветошкин А.С., Симонян А.А., Гапон Л.И., Карева М.А. Артериальная гипертония в условиях вахты в Арктике: особенности взаимосвязей жесткости артерий с маркерами воспаления и некоторыми метаболическими факторами риска. Российский кардиологический журнал. 2023;28(4):5167. https://doi.org/10.15829/1560-4071-2023-167
115. Мордовин В.Ф., Зюбанова И.В., Манукян М.А., Доржиева И.К., Вторушина А.А., Хунхинова С.А. и др. Роль иммуновоспалительных механизмов в патогенезе артериальной гипертонии. Сибирский журнал клинической и экспериментальной медицины. 2023;38(1):21–27. https://doi.org/10.29001/2073-8552-2023-38-1-21-27
116. Павлова О.С., Ясюкайть Н.В., Барбук О.А., Денисевич Т.Л., Затолока Н.В., Русских И.И. и др. Ассоциация показателей воспаления и гематологических индексов с гипертрофией левого желудочка у пациентов с артериальной гипертензией. Артериальная гипертензия. 2024;30(1):108–120. https://doi.org/10.18705/1607-419X-2024-2405
117. Павлова О. С., Ясюкайть Н. В., Денисевич Т. Л., Барбук О.А., Русских И.И. Ассоциация показателей воспаления и гематологических индексов с субклиническим поражением почек у пациентов с артериальной гипертензией. Российский кардиологический журнал. 2026;31(3):6504. https://doi.org/10.15829/1560-4071-2026-6504
118. Васильева Л. В., Брежнева Н. А., Купцов М. А., Попов С.Ю. Суслова Е.Ю., Гостева Е. В. и др. Связь суточного профиля артериального давления с биомаркерами крови у пациентов пожилого возраста с артериальной гипертензией и обструктивным апноэ сна. Вестник современной клинической медицины. 2026;19(1):22–30. https://doi.org/10.20969/VSKM.2026.19(1).22-30
119. Губарева И.В., Пашенцева А.В., Вуколова Ю.Ю., Савельева Н.В., Шван Л.Ю. Стратегии выбора комбинированной терапии артериальной гипертензии при метаболическом синдроме — фокус на воспаление. Экспериментальная и клиническая гастроэнтерология. 2024;222(2):31–36. https://doi.org/10.31146/1682-8658-ecg-222-2-31-36
120. MurrayE, Nosalski R, MacRitchie N, Tomaszewski M, Maffia P, Harrison D, et al. Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective. Cardiovasc Res. 2021; 117(13):2589–2609. https://doi.org/10.1093/cvr/cvab330
121. Awad K, Zaki MM, Mohammed M, Lewek J, Lavie CJ, Banach M. Effect of the renin-angiotensin system inhibitors on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2022;97(10):1808–1823. https://doi.org/10.1016/j.mayocp.2022.06.036
122. Агарков Н.М., Макконен К.Ф., Титов А.А., Бельчикова Д.Н., Колпина Л.В. Иммунный плейотропный эффект телмисартана при артериальной гипертензии. Медицинская иммунология. 2022;24(4):831–836. https://doi.org/10.15789/1563-0625-IPE-2476
123. Chavan S, Pavlov V, Tracey K. Mechanisms and therapeutic relevance of neuro-immune communication. Immunity. 2017;46(6):927–942. https://doi.org/10.1016/j.immuni.2017.06.008
124. Reardon C, Murray K, Lomax A. Neuroimmune communication in health and disease. Physiol Rev. 2018;98(4):2287–2316. https://doi.org/10.1152/physrev.00035.2017
125. Carnevale D. Neural control of immunity in hypertension: Council on Hypertension Mid Career Award for Research Excellence, 2019. Hypertension. 2020;76(3):622–628. https://doi.org/10.1161/HYPERTENSIONAHA.120.14637
126. Esler M, Krum H, Sobotka P, Schlaich M, Schmieder R, Böhm M, et al. Renal sympathetic denervation in patients with treatment-resistant HTN (the SYMPLICITY HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–1909. https://doi.org/10.1016/S0140-6736(10)62039-9
127. Pekarsky S, Mordovin V, Semke G, Ripp T. A method to improve efficacy of ABPM in evaluation of hypertension. J Hypertens. 2011;29:e309–e310. https://doi.org/10.1097/00004872-201106001-00891
128. Pekarskiy S, Baev A, Mordovin V, Semke G, Ripp T, Falkovskaya A, et al. Denervation of the distal renal arterial branches vs. conventional main renal artery treatment: a randomized controlled trial for treatment of resistant hypertension. J Hypertens. 2017;35(2):369–375. https://doi.org/10.1097/HJH.0000000000001160
129. Baev A, Pekarskiy S, Mordovin V, Ripp T, Falkovskaya A, Lichikaki V. A distal mode of renal denervation in segmental branches of renal artery versus conventional main trunk therapy: a double blind randomized controlled study in patients with resistant hypertension. J Am Coll Cardiol. 2017;70(18):B86. https://doi.org/10.1016/j.jacc.2017.09.277
130. Kandzari D, Bohm M, Mahfoud F, Townsend R, Weber M, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–2355. https://doi.org/10.1016/S0140-6736(18)30951-6
131. Azizi M, Schmieder R, Mahfoud F, Weber M, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–2345. https://doi.org/10.1016/S0140-6736(18)31082-1
132. Townsend R, Mahfoud F, Kandzari D, Kario K, Pocock S, Weber M, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160– 2170. https://doi.org/10.1016/S0140-6736(17)32281-X
133. Mahfoud F, Mancia G, Schmieder R, Narkiewicz K, Ruilope L, Schlaich M, et al. Renal denervation in high-risk patients with hypertension. J Am Coll Cardiol. 2020;75(23):2879–2888. https://doi.org/10.1016/j.jacc.2020.04.036
134. Ситкова Е.С., Мордовин В.Ф., Рипп Т.М., Пекарский С. Е., Рябова Т. Р., Личикаки В. А. и др. Положительное влияние ренальной денервации на гипертрофию и субэндокардиальное повреждение миокарда. Артериальная гипертензия. 2019;25(1):46–59. https://doi.org/10.18705/1607-419X-2019-25-1-46-59
135. Ситкова Е. С., Мордовин В. Ф., Пекарский С. Е., Рипп Т. М., Фальковская А.Ю., Личикаки В. А. и др. Дистальная ренальная денервация: возможности кардиопротекции у пациентов с резистентной артериальной гипертонией. Кардиоваскулярная терапия и профилактика. 2020;19(4):2225. https://doi.org/10.15829/1728-8800-2019-2225
136. Kordalis A, Tsiachris D, Pietri P, Tsioufis C, Stefanadis C. Regression of organ damage following renal denervation in resistant hypertension: a meta-analysis. J Hypertens. 2018;36(8):1614–1621. https://doi.org/10.1097/HJH.0000000000001798
137. Xiao L, Kirabo A, Wu J, Saleh M, Zhu L, Wang F, et al. Renal denervation prevents immune cell activation and renal inflammation in angiotensin II-induced hypertension. Circ Res. 2015;117(6):547–557. https://doi.org/10.1161/CIRCRESAHA.115.306010
138. Harwani S, Raikwar N, Ratcliff J, Allamargot C, Chapleau M, Abboud F. Renal denervation prevents cholinergic mediated hypertension and renal macrophage infiltration. Circulation. 2017;136(1):А20885. https://doi.org/10.1161/circ.136.suppl_1.20885
139. Dörr О, Liebetrau С, Möllmann Н, Mahfoud F, Ewen S, Gaede L, et al. Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension. Clin Res Cardiol. 2015;104(2):175–184. https://doi.org/10.1007/s00392-014-0773-4
140. Солонская Е.И., Мочула О.В., Мордовин В.Ф., Зюбанова И.В., Манукян М. А., Личикаки В. А. и др. Регресс гипертрофии левого желудочка у больных резистентной артериальной гипертонией после ренальной денервации: роль гемодинамических и антифибротических эффектов. Российский кардиологический журнал. 2024;29(5):5654. https://doi.org/10.15829/1560-4071-2024-5654
141. Зюбанова И.В., Мордовин В.Ф., Пекарский С.Е., Рипп Т.М., Фальковская А.Ю., Личикаки В.А. и др. Возможные механизмы отдаленных кардиальных эффектов ренальной денервации. Артериальная гипертензия. 2019;25(4):423–432. https://doi.org/10.18705/1607-419X-2019-25-4-423-432
142. Фальковская А.Ю., Мордовин В.Ф., Пекарский С.Е., Рипп Т.М., Личикаки В.А., Ситкова Е.С. и др. Влияние ренальной денервации на уровень адипокинов и провоспалительный статус у больных резистентной артериальной гипертонией, ассоциированной с сахарным диабетом 2-го типа. Сибирский журнал клинической и экспериментальной медицины. 2019;34(4):118–127. https://doi.org/10.29001/2073-8552-2019-34-4-118-127